Table 5 Adverse effects and pathological findings indicators
From: Multicentre clinical radiotherapy audit in rectal cancer: results of the IROCA project
INDICATORS | ICO-B | ICO-G | ICO H | IPO | NO | WCO | All | ||
|---|---|---|---|---|---|---|---|---|---|
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N | % | P | |
Post-surgery ypT | 33 (82.5) | 36 (90.0) | 40 (100.0) | 33 (84.6) | 16 (72.7) | 38 (95.0) | 196 | 88.7 | 0.013 |
Post-surgery ypN | 34 (85.0) | 36 (90.0) | 38 (95.0) | 33 (84.6) | 16 (72.7) | 38 (95.0) | 195 | 88.2 | 0.086 |
Patients with adjuvant treatment – chemotherapy | 28 (70.0) | 35 (87.5) | 27 (67.5) | 28 (71.8) | 8 (36.4) | 20 (50.0) | 146 | 66.1 | 0.000 |
SIDE EFFECTS (≥ grade 3) | |||||||||
Acute (< 6 mo) | |||||||||
Rectitis | 4 (10.0) | 1 (2.5) | 0 (0.0) | 0 (0.0) | 1 (4.5) | 2 (5.0) | 8 | 3.6 | 0.153 |
Cystitis-urethritis | 0 (0.0) | 0 (0.0) | 1 (2.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 | 0.5 | 0.474 |
Neutropenia | 5 (12.5) | 0 (0.0) | 0 (0.0) | 2 (5.1) | 0 (0.0) | 0 (0.0) | 7 | 3.2 | 0.006 |
Diarrhea | 0 (0.0) | 4 (10.0) | 3 (7.5) | 1 (2.6) | 1 (4.5) | 2 (5.0) | 11 | 5.0 | 0.385 |
Chronic (> 6 mo) | |||||||||
Rectitis | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 | 0.0 | – |
Cystitis-urethritis | 0 (0.0) | 1 (2.5) | 2 (5.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 | 1.4 | 0.279 |
Neutropenia | 1 (2.5) | 2 (5.0) | 3 (7.5) | 1 (2.6) | 0 (0.0) | 0 (0.0) | 7 | 3.2 | 0.414 |
Diarrhea | 3 (7.5) | 0 (0.0) | 3 (7.5) | 2 (5.1) | 0 (0.0) | 0 (0.0) | 8 | 3.6 | 0.184 |